| Interfering with pH regulation in tumours as a therapeutic strategy. | |
| | |
MedLine Citation:
|
PMID: 21921921 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The high metabolic rate of tumours often leads to acidosis and hypoxia in poorly perfused regions. Tumour cells have thus evolved the ability to function in a more acidic environment than normal cells. Key pH regulators in tumour cells include: isoforms 2, 9 and 12 of carbonic anhydrase, isoforms of anion exchangers, Na(+)/HCO(3)(-) co-transporters, Na(+)/H(+) exchangers, monocarboxylate transporters and the vacuolar ATPase. Both small molecules and antibodies targeting these pH regulators are currently at various stages of clinical development. These antitumour mechanisms are not exploited by the classical cancer drugs and therefore represent a new anticancer drug discovery strategy. |
| | |
Authors:
|
Dario Neri; Claudiu T Supuran |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-16 |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: - ISSN: 1474-1784 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zürich, Wolfgang Pauli Strasse 10, CH-8093, Zürich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of subtype-selective oestrogen receptor-based therapeutics.
Next Document: Haplotype phasing: existing methods and new developments.